361 related articles for article (PubMed ID: 16050407)
1. [Renin-angiotensin system in diabetic nephropathy].
Luño J
Nefrologia; 2005; 25 Suppl 2():73-81. PubMed ID: 16050407
[TBL] [Abstract][Full Text] [Related]
2. [In the DETAIL. Kidney protection in manifestations of microalbuminuria].
MMW Fortschr Med; 2006 Jun; 148(26):51. PubMed ID: 16875382
[No Abstract] [Full Text] [Related]
3. Angiotensin blockade in type 2 diabetic renal disease.
Ruilope LM; Luño J
Kidney Int Suppl; 2002 Dec; (82):S61-3. PubMed ID: 12410857
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy].
Philips JC; Weekers L; Scheen AJ
Rev Med Liege; 2001 Feb; 56(2):126-8. PubMed ID: 11294048
[TBL] [Abstract][Full Text] [Related]
6. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
7. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
Hunsicker LG
J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
[TBL] [Abstract][Full Text] [Related]
8. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Van Buren PN; Adams-Huet B; Nguyen M; Molina C; Toto RD
Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Burnier M; Zanchi A
J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
[TBL] [Abstract][Full Text] [Related]
10. [Debate concerning the optimal blockage of the renin-angiotensin system].
Choukroun G
Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
[No Abstract] [Full Text] [Related]
11. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
12. [Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Goicolea I; Fernández González R; Piniés J; Garrido J; Martínez JM; Armenteros S; Moreno Carretero E
Nefrologia; 2002; 22(2):170-8. PubMed ID: 12085418
[TBL] [Abstract][Full Text] [Related]
13. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
14. [Control of arterial pressure in diabetic nephropathy].
Luño J; García de Vinuesa S
Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
[No Abstract] [Full Text] [Related]
15. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Rossing K; Christensen PK; Jensen BR; Parving HH
Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
Pathak JV; Dass EE
Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.
Parvanova A; Chiurchiu C; Ruggenenti P; Remuzzi G
Expert Opin Pharmacother; 2005 Sep; 6(11):1931-42. PubMed ID: 16144512
[TBL] [Abstract][Full Text] [Related]
18. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
Bichu P; Nistala R; Khan A; Sowers JR; Whaley-Connell A
Vasc Health Risk Manag; 2009; 5(1):129-40. PubMed ID: 19436679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
